Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Giles

Showing results (331-340 of 676) with videos related to

Pageof 68
Sort By:
BMJ Open|January 21, 2021
Protocol for a non-randomised feasibility study evaluating a codesigned patient safety guide in primary careRebecca L Morris, Kay Gallacher, Mark Hann, et al.
Clinical Advances in Hematology & Oncology : H&O|October 15, 2005
Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapseLance H Leopold, Mark S Berger, Su-Chun Cheng, et al.
Inorganic Chemistry|December 7, 2017
Cobalt- and Rhodium-Corrole-Triphenylphosphine Complexes Revisited: The Question of a Noninnocent CorroleSumit Ganguly, Diemo Renz, Logan J Giles, et al.
Expert Review of Anticancer Therapy|January 28, 2015
Targeted therapy of acute myeloid leukemiaBenedito A Carneiro, Jessica K Altman, Jason B Kaplan, et al.
American Journal of Hematology|February 19, 2000
Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocolF J Giles, N R Wickham, B L Rapoport, et al.
Journal of Cellular and Molecular Medicine|November 25, 2010
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinibKevin R Kelly, Jeffrey Ecsedy, Ernest Medina, et al.
British Journal of Haematology|March 11, 2004
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluationNada Orsolic, Francis J Giles, Henriette Gourdeau, et al.
Oncology Letters|November 9, 2018
Aberrant expression of glycogen synthase kinase-3β in human breast and head and neck cancerAndrey V Ugolkov, Maria Matsangou, Timothy J Taxter, et al.
Leukemia & Lymphoma|January 28, 1999
Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemiaM Beran, E Estey, S M O'Brien, et al.
AJR. American Journal of Roentgenology|December 24, 2009
Clinical utility of PET/CT in lymphomaCarmel G Cronin, Ronan Swords, Mylene T Truong, et al.
Pageof 68

Showing results (331-340 of 676) with videos related to

Sort By:
Pageof 68
BMJ Open|January 21, 2021
Protocol for a non-randomised feasibility study evaluating a codesigned patient safety guide in primary careRebecca L Morris, Kay Gallacher, Mark Hann, et al.
Clinical Advances in Hematology & Oncology : H&O|October 15, 2005
Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapseLance H Leopold, Mark S Berger, Su-Chun Cheng, et al.
Inorganic Chemistry|December 7, 2017
Cobalt- and Rhodium-Corrole-Triphenylphosphine Complexes Revisited: The Question of a Noninnocent CorroleSumit Ganguly, Diemo Renz, Logan J Giles, et al.
Expert Review of Anticancer Therapy|January 28, 2015
Targeted therapy of acute myeloid leukemiaBenedito A Carneiro, Jessica K Altman, Jason B Kaplan, et al.
American Journal of Hematology|February 19, 2000
Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocolF J Giles, N R Wickham, B L Rapoport, et al.
Journal of Cellular and Molecular Medicine|November 25, 2010
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinibKevin R Kelly, Jeffrey Ecsedy, Ernest Medina, et al.
British Journal of Haematology|March 11, 2004
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluationNada Orsolic, Francis J Giles, Henriette Gourdeau, et al.
Oncology Letters|November 9, 2018
Aberrant expression of glycogen synthase kinase-3β in human breast and head and neck cancerAndrey V Ugolkov, Maria Matsangou, Timothy J Taxter, et al.
Leukemia & Lymphoma|January 28, 1999
Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemiaM Beran, E Estey, S M O'Brien, et al.
AJR. American Journal of Roentgenology|December 24, 2009
Clinical utility of PET/CT in lymphomaCarmel G Cronin, Ronan Swords, Mylene T Truong, et al.
Pageof 68